ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
0,033 USD
arrow_downward
−12,00%(−0,0045) 1D
10. srp, 16:00:00 GMT -4 · USD
search
Svi simboli
1D
5D
1M
6M
GDD
1G
5G
MAKS
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za ADAPY...
Otvori
0,04 USD
Najviša
0,04 USD
Najniža
0,03 USD
Trž. kap.
8,20 mil.
Prosj. kol.
586,01 tis.
Količina
44,05 tis.
52-tjed. najviša
0,36 USD
52-tjed. najniža
0,00 USD
Beta
0,90
Dionice u optjecaju
265,05 mil.
Broj djelatnika
272
Otvori
0,04 USD
Najviša
0,04 USD
Najniža
0,03 USD
Trž. kap.
8,20 mil.
Prosj. kol.
586,01 tis.
Količina
44,05 tis.
52-tjed. najviša
0,36 USD
52-tjed. najniža
0,00 USD
Beta
0,90
Dionice u optjecaju
265,05 mil.
Broj djelatnika
272
Vijesti
Iz izvora na cijelom webu
Naslovi.net
·
prije 1 dan
Wall Street: S&P 500 porastao na kraju tjedna
Yahoo Finance
·
prije 1 sat
SK Hynix shares fall as much as 4.4% in Seoul after strong Nasdaq debut
Moomoo
·
prije 32 minute
Moomoo Markets Look Ahead for Monday, July 13
marketscreener.com
·
prije 1 sat
Bending Spoons S.p.A.(NasdaqGS: BSP) added to S&P Global BMI Index
Profil
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Adaptimmune Therapeutics PLC - ADR – informacije
Glavni izvršni direktorAdrian Rawcliffe
Zaposlenici272
Osnovano2008
Sjedište-
Sektor-
Web-lokacijaadaptimmune.com
AI sadržaj može uključivati pogreške. Saznajte više